(Q49022238)

English

Effect of aliskiren in patients with heart failure according to background dose of ACE inhibitor: a retrospective analysis of the Aliskiren Observation of Heart Failure Treatment (ALOFT) trial.

scientific article published in August 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/21779784

Effect of aliskiren in patients with heart failure according to background dose of ACE inhibitor: a retrospective analysis of the Aliskiren Observation of Heart Failure Treatment (ALOFT) trial. (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/21779784

0 references

Aldo P. Maggioni

4

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/21779784

7

object named as

Bertram Pitt

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

8

object named as

John J V McMurray

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/21779784

author name string

Novalia P Sidik

1

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/21779784

Scott D Solomon

2

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/21779784

Roberto Latini

3

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/21779784

Melanie Wright

5

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/21779784

Claudio R Gimpelewicz

6

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/21779784

publication date

1 August 2011

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/21779784

Cardiovascular Drugs and Therapy

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/21779784

25

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/21779784

4

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/21779784

315-321

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/21779784

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

1 reference

https://api.crossref.org/works/10.1007%2FS10557-011-6319-3

21 January 2018

Eplerenone in patients with systolic heart failure and mild symptoms

1 reference

https://api.crossref.org/works/10.1007%2FS10557-011-6319-3

21 January 2018

A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure

1 reference

https://api.crossref.org/works/10.1007%2FS10557-011-6319-3

21 January 2018

Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial

1 reference

https://api.crossref.org/works/10.1007%2FS10557-011-6319-3

21 January 2018

Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysi

1 reference

https://api.crossref.org/works/10.1007%2FS10557-011-6319-3

21 January 2018

Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS10557-011-6319-3

21 January 2018

Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both

1 reference

https://api.crossref.org/works/10.1007%2FS10557-011-6319-3

21 January 2018

Telmisartan, ramipril, or both in patients at high risk for vascular events

1 reference

https://api.crossref.org/works/10.1007%2FS10557-011-6319-3

21 January 2018

Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure

1 reference

https://api.crossref.org/works/10.1007%2FS10557-011-6319-3

21 January 2018

ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology

1 reference

https://api.crossref.org/works/10.1007%2FS10557-011-6319-3

21 January 2018

B-type natriuretic peptide-guided heart failure therapy: A meta-analysis

1 reference

https://api.crossref.org/works/10.1007%2FS10557-011-6319-3

21 January 2018

Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitivity C-reactive peptide and N-terminal pro B-type natriuretic peptide

1 reference

https://api.crossref.org/works/10.1007%2FS10557-011-6319-3

21 January 2018

Usefulness of temporal changes in neurohormones as markers of ventricular remodeling and prognosis in patients with left ventricular systolic dysfunction and heart failure receiving either candesartan or enalapril or both

1 reference

https://api.crossref.org/works/10.1007%2FS10557-011-6319-3

21 January 2018

Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators

1 reference

https://api.crossref.org/works/10.1007%2FS10557-011-6319-3

21 January 2018

Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)–Added trial

1 reference

https://api.crossref.org/works/10.1007%2FS10557-011-6319-3

21 January 2018

Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (

1 reference

https://api.crossref.org/works/10.1007%2FS10557-011-6319-3

21 January 2018

Identifiers

10.1007/S10557-011-6319-3

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/21779784

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 February 2018

http://europepmc.org/abstract/MED/21779784

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q49022238&oldid=1577084995"